Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?
- 作者:Farhanah Yousaf ; Bruce Spinowitz
- 关键词:Hypoxia ; inducible factor ; HIF ; 1α ; HIF ; 2 α ; Anemia ; Erythropoietin ; Iron ; Prolyl ; hydroxylase domain ; PHD inhibitors ; Hypertension ; Nitric oxide ; Pulmonary hypertension
- 刊名:Current Hypertension Reports
- 出版年:2016
- 出版时间:March 2016
- 年:2016
- 卷:18
- 期:3
- 全文大小:559 KB
- 参考文献:1.Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631–4.PubMed PubMedCentral CrossRef
2.Stivelman JC. Benefits of anaemia treatment on cognitive function. Nephrol Dial Transplant. 2000;15 Suppl 3:29–35.PubMed CrossRef
3.Portolés J, López-Gómez JM, Aljama P. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study. Nephrol Dial Transplant. 2007;22(2):500–7.PubMed CrossRef
4.Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999 Mar;10(3):610–9.
5.Karaboyas A, Zee J, Morgenstern H, Nolen JG, Hakim R, Kalantar-Zadeh K, et al. Understanding the recent increase in ferritin levels in United States dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephrol. 2015;10(10):1814–21.PubMed CrossRef
6.Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25(4):548–54.PubMed CrossRef
7.United States Renal Data System, USRDS. 2012 Annual Data Report: atlas of chronic kidney and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
8.McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013;37(6):549–58.PubMed CrossRef
9.Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990;300(6724):573–8.CrossRef
10.Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron. 1992;60(4):390–6.PubMed CrossRef
11.Abraham PA, Opsahl JA, Keshaviah PR, Collins AJ, Whalen JJ, Asinger RW, et al. Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. Am J Kidney Dis. 1990;16(5):438–46.PubMed CrossRef
12.Bahlmann J, Schöter KH, Scigalla P, Gurland HJ, Hilfenhaus M, Koch KM, et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contrib Nephrol. 1991;88:90–106.PubMed CrossRef
13.Teehan BP, Benz RL, Sigler MH, Brown JM. Early intervention with recombinant human erythropoietin therapy. Semin Nephrol. 1990;10(2 Suppl 1):28–34.PubMed
14.Bommer J, Müller-Bühl E, Ritz E, Eifert J. Recombinant human erythropoietin in anaemic patients on haemodialysis. Lancet. 1987;1(8529):392.PubMed CrossRef
15.Bommer J, Alexiou C, Müller-Bühl U, Eifert J, Ritz E. Recombinant human erythropoietin therapy in haemodialysis patients—dose determination and clinical experience. Nephrol Dial Transplant. 1987;2(4):238–42.PubMed
16.Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J (Clin Res Ed). 1987;295(6605):1017–20.CrossRef
17.Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111(12):992–1000.PubMed CrossRef
18.Sundal E, Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year’s treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant. 1989;4(11):979–87.PubMed
19.Samtleben W, Baldamus CA, Bommer J, Fassbinder W, Nonnast-Daniel B, Gurland HJ. Blood pressure changes during treatment with recombinant human erythropoietin. Contrib Nephrol. 1988;66:114–22.PubMed CrossRef
20.Pollok M, Bommer J, Gurland HJ, Koch KM, Schoeppe W, Scigalla P, et al. Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study. Contrib Nephrol. 1989;76:201–11. discussion 212-8.PubMed CrossRef
21.Nonnast-Daniel B, Deschodt G, Brunkhorst R, Creutzig A, Bahlmann J, Shaldon S, et al. Long-term effects of treatment with recombinant human erythropoietin on haemodynamics and tissue oxygenation in patients with renal anaemia. Nephrol Dial Transplant. 1990;5(6):444–8.PubMed CrossRef
22.Akizawa T, Koshikawa S, Takaku F, Urabe A, Akiyama N, Mimura N, et al. Clinical effect of recombinant human erythropoietin on anemia associated with chronic renal failure. A multi-institutional study in Japan. Int J Artif Organs. 1988;11(5):343–50.PubMed
23.Baskin S, Lasker N. Erythropoietin-associated hypertension. N Engl J Med. 1990;323(14):999–1000.PubMed CrossRef
24.Schaefer RM, Leschke M, Strauer BE, Heidland A. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. Am J Nephrol. 1988;8(6):449–53.PubMed CrossRef
25.Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol. 2004;15(12):3154–65.PubMed CrossRef
26.Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369(9559):381–8.PubMed CrossRef
27.Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol. 2009;4(2):470–80.PubMed CrossRef
28.Cody J, Daly C, Campbell M, Donaldson C, Khan I, Vale L, et al. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients. Cochrane Database Syst Rev. 2005;3, CD003895.PubMed
29.Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014;12, CD010590.PubMed
30.Annuk M, Linde T, Lind L, Fellström B. Erythropoietin impairs endothelial vasodilatory function in patients with renal anemia and in healthy subjects. Nephron Clin Pract. 2006;102(1):c30–4.PubMed CrossRef
31.Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol. 1994;4(11):1874–8.PubMed
32.Kumar H, Choi DK. Hypoxia inducible factor pathway and physiological adaptation: a cell survival pathway? Mediat Inflamm. 2015;2015:584758.CrossRef
33.Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12(12):5447–54.PubMed PubMedCentral CrossRef
34.Hara S, Hamada J, Kobayashi C, Kondo Y, Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. Biochem Biophys Res Commun. 2001;287(4):808–13.PubMed CrossRef
35.Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468–72.PubMed CrossRef
36.Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464–8.PubMed CrossRef
37.Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.PubMed CrossRef
38.Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002;16(12):1466–71.PubMed PubMedCentral CrossRef
39.Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem. 2002;277(29):26351–5.PubMed CrossRef
40.Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002;295(5556):858–61.PubMed CrossRef
41.•
Greer SN, Metcalf JL, Wang Y, Ohh M. The updated biology of hypoxia-inducible factor. EMBO J. 2012;31(11):2448–60. Summarizes the regulation of HIF and relevant biological processes.PubMed PubMedCentral CrossRef
42.Choudhry H, Schödel J, Oikonomopoulos S, Camps C, Grampp S, Harris AL, et al. Extensive regulation of the non-coding transcriptome by hypoxia: role of HIF in releasing paused RNApol2. EMBO Rep. 2014;15(1):70–6.PubMed PubMedCentral CrossRef
43.•
Schödel J, Mole DR, Ratcliffe PJ. Pan-genomic binding of hypoxia-inducible transcription factors. Biol Chem. 2013;394(4):507–17. Reviews HIF binding sites that have been identified.PubMed CrossRef
44.Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci U S A. 2007;104(7):2301–6.PubMed PubMedCentral CrossRef
45.Scortegagna M, Ding K, Zhang Q, Oktay Y, Bennett MJ, Bennett M, et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood. 2005;105(8):3133–40.PubMed CrossRef
46.Paliege A, Rosenberger C, Bondke A, Sciesielski L, Shina A, Heyman SN, et al. Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int. 2010;77(4):312–8.PubMed CrossRef
47.Furlow PW, Percy MJ, Sutherland S, Bierl C, McMullin MF, Master SR, et al. Erythrocytosis-associated HIF-2alpha mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline. J Biol Chem. 2009;284(14):9050–8.PubMed PubMedCentral CrossRef
48.Martini M, Teofili L, Cenci T, Giona F, Torti L, Rea M, et al. A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica. 2008;93(7):1068–71.PubMed CrossRef
49.Simpson RJ, McKie AT. Iron and oxygen sensing: a tale of 2 interacting elements? Metallomics. 2015;7(2):223–31.PubMed CrossRef
50.van Wijk R, Sutherland S, Van Wesel AC, Huizinga EG, Percy MJ, Bierings M, et al. Erythrocytosis associated with a novel missense mutation in the HIF2A gene. Haematologica. 2010;95(5):829–32.PubMed PubMedCentral CrossRef
51.Bosch-Marce M, Okuyama H, Wesley JB, Sarkar K, Kimura H, Liu YV, et al. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res. 2007;101(12):1310–8.PubMed CrossRef
52.Wheaton WW, Chandel NS. Hypoxia. 2. Hypoxia regulates cellular metabolism. Am J Physiol Cell Physiol. 2011;300(3):C385–93.PubMed PubMedCentral CrossRef
53.Berra E, Benizri E, Ginouvès A, Volmat V, Roux D, Pouysségur J. HIF
prolyl-
hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 2003;22(16):4082–90.PubMed PubMedCentral CrossRef
54.Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, et al. Differential function of the
prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004;279(37):38458–65.PubMed CrossRef
55.Takeda K, Aguila HL, Parikh NS, Li X, Lamothe K, Duan LJ, et al. Regulation of adult erythropoiesis by
prolyl hydroxylase domain proteins. Blood. 2008;111(6):3229–35.PubMed PubMedCentral CrossRef
56.Laitala A, Aro E, Walkinshaw G, Mäki JM, Rossi M, Heikkilä M, et al. Transmembrane
prolyl 4-
hydroxylase is a fourth
prolyl 4-
hydroxylase regulating EPO production and erythropoiesis. Blood. 2012;120(16):3336–44.PubMed CrossRef
57.Minamishima YA, Kaelin Jr WG. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science. 2010;329(5990):407.PubMed PubMedCentral CrossRef
58.Bishop T, Gallagher D, Pascual A, Lygate CA, de Bono JP, Nicholls LG, et al. Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice. Mol Cell Biol. 2008;28(10):3386–400.PubMed PubMedCentral CrossRef
59.Sato Y, Yanagita M. Renal anemia: from incurable to curable. Am J Physiol Renal Physiol. 2013;305(9):F1239–48.PubMed CrossRef
60.Nagai T, Yasuoka Y, Izumi Y, Horikawa K, Kimura M, Nakayama Y, et al. Reevaluation of erythropoietin production by the nephron. Biochem Biophys Res Commun. 2014;449(2):222–8.PubMed CrossRef
61.•
Gerl K, Miquerol L, Todorov VT, Hugo CP, Adams RH, Kurtz A, et al. Inducible glomerular erythropoietin production in the adult kidney. Kidney Int. 2015;88(6):1345–55. Describes other renal cells that can be induced to express EPO.PubMed CrossRef
62.Kurt B, Paliege A, Willam C, Schwarzensteiner I, Schucht K, Neymeyer H, et al. Deletion of von Hippel-Lindau protein converts renin-producing cells into erythropoietin-producing cells. J Am Soc Nephrol. 2013;24(3):433–44.PubMed PubMedCentral CrossRef
63.Kurt B, Gerl K, Karger C, Schwarzensteiner I, Kurtz A. Chronic hypoxia-inducible transcription factor-2 activation stably transforms juxtaglomerular renin cells into fibroblast-like cells in vivo. J Am Soc Nephrol. 2015;26(3):587–96.PubMed PubMedCentral CrossRef
64.Plotkin MD, Goligorsky MS. Mesenchymal cells from adult kidney support angiogenesis and differentiate into multiple interstitial cell types including erythropoietin-producing fibroblasts. Am J Physiol Renal Physiol. 2006;291(4):F902–12.PubMed CrossRef
65.Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007;117(4):1068–77.PubMed PubMedCentral CrossRef
66.Bernaudin M, Bellail A, Marti HH, Yvon A, Vivien D, Duchatelle I, et al. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia. 2000;30(3):271–8.PubMed CrossRef
67.Weidemann A, Kerdiles YM, Knaup KX, Rafie CA, Boutin AT, Stockmann C, et al. The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J Clin Invest. 2009;119(11):3373–83.PubMed PubMedCentral
68.Rankin EB, Wu C, Khatri R, Wilson TL, Andersen R, Araldi E, et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell. 2012;149(1):63–74.PubMed PubMedCentral CrossRef
69.Chiang CK, Tanaka T, Inagi R, Fujita T, Nangaku M. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Investig. 2011;91(11):1564–71.PubMed CrossRef
70.Pasqualetti P, Casale R. Circadian rhythm of serum erythropoietin in healthy subjects. Riv Eur Sci Med Farmacol. 1996;18(3):91–3.PubMed
71.Egg M, Köblitz L, Hirayama J, Schwerte T, Folterbauer C, Kurz A, et al. Linking oxygen to time: the bidirectional interaction between the hypoxic signaling pathway and the circadian clock. Chronobiol Int. 2013;30(4):510–29.PubMed CrossRef
72.Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev. 1992;72(2):449–89.PubMed
73.•
Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif. 2010;29(2):86–92. Reviews the two types of EPO receptors and their implications.PubMed CrossRef